Hypersensitivity News and Research RSS Feed - Hypersensitivity News and Research

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm. [More]
FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. [More]
NASA study reveals how spaceflight affects immune system of crew members

NASA study reveals how spaceflight affects immune system of crew members

There is nothing like a head cold to make us feel a little dazed. We get things like colds and the flu because of changes in our immune system. Researchers have a good idea what causes immune system changes on Earth-think stress, inadequate sleep and improper nutrition. [More]
New research finds that early use of antibiotics can alter immunity later on

New research finds that early use of antibiotics can alter immunity later on

New University of British Columbia research found that receiving antibiotic treatments early in life can increase susceptibility to specific diseases later on. [More]
Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

The U.S. Food and Drug Administration today granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. [More]
Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. [More]
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. [More]
Access Pharmaceuticals enters into exclusive license agreement with Norgine

Access Pharmaceuticals enters into exclusive license agreement with Norgine

ACCESS PHARMACEUTICALS, INC., an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with Norgine B.V., a leading independent European specialty pharmaceutical company, for the commercialization of MuGard in Europe. [More]
Researchers find differences in brain wiring between children with SPD and those with autism

Researchers find differences in brain wiring between children with SPD and those with autism

Researchers at UC San Francisco have found that children with sensory processing disorders have decreased structural brain connections in specific sensory regions different than those in autism, further establishing SPD as a clinically important neurodevelopmental disorder. [More]
GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Urge incontinence therapy may relieve stress incontinence

Urge incontinence therapy may relieve stress incontinence

Anticholinergic medication appears to be effective as a treatment for stress and mixed urinary incontinence, results of a small clinical trial indicate. [More]
New research opens up potential new therapeutic targets for hard-to-treat food allergy

New research opens up potential new therapeutic targets for hard-to-treat food allergy

New research in Nature Genetics identifies a novel genetic and molecular pathway in the esophagus that causes eosinophillic esophagitis (EoE), opening up potential new therapeutic strategies for an enigmatic and hard-to-treat food allergy. [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
New method to repair pain

New method to repair pain

A study published in the scientific journal Nature Neuroscience by Yves De Koninck and Robert Bonin, two researchers at Universit- Laval, reveals that it is possible to relieve pain hypersensitivity using a new method that involves rekindling pain so that it can subsequently be erased. [More]
Researchers discover how metal beryllium triggers deadly immune response in the lungs

Researchers discover how metal beryllium triggers deadly immune response in the lungs

Using exquisitely detailed maps of molecular shapes and the electrical charges surrounding them, researchers at National Jewish Health have discovered how the metal beryllium triggers a deadly immune response in the lungs. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide. [More]